Elhan S. has extensive experience in the oncology field, serving as a Medical Advisor at Bayer HealthCare from November 2012 to January 2015, where responsibilities included developing brand medical strategies for Nexavar and leading prelaunch activities and observational studies. Subsequently, Elhan served as a Medical Advisor at AstraZeneca from February 2015 to July 2019, focusing on brand strategies for Lynparza, Faslodex, and Zoladex in various cancers, and contributed to significant events such as advisory boards and the launch of Faslodex for HR positive breast cancer. Currently, Elhan holds the position of Medical Director in Early Global Development at AstraZeneca, overseeing Phase 1/2 trials in immuno-oncology and DNA damage repair agents. Additional experience includes roles in cardiovascular surgery, oncological urology, and clinical research fellowships, complemented by a medical degree from First Moscow State Medical University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices